-
Citi Lowers Genzyme (GENZ) Price Target
Wednesday, June 30, 2010 - 10:29amCiti Investment Research & Analysis analyst Yaron Werber maintained a Buy/High Risk rating for shares of Genzyme Corporation (Nasdaq: GENZ), while lowering the stock's price target to $64 per share, down from the previous price target of $66. Werber said that Genzyme (GENZ) announced further (...
Read More >> -
Citi Rates Rates Amgen (AMGN) A Medium Risk Buy
Tuesday, June 8, 2010 - 9:29am
Citi Investment Research & Analysis analysts Yaron Werber, Navdeep Singh and Karim De felipe maintained their Buy/Medium Risk rating for shares of Amgen Inc (Nasdaq: AMGN), with a price target of $64 per share. The analysts said that most regulatory hurdles for Amgen Inc's Dmab have been...
Read More >> -
31.8% Return Expected in Gilead Sciences, Further Upside Possible (GILD)
Tuesday, December 29, 2009 - 3:28pmCiti Investment Research analyst Yaron Werber has kept the target price of $57 per share unchanged for Gilead Sciences Inc. (NASDAQ: GILD), stating that the consensus numbers look conservative and further upside is possible given Gilead’s substantial expense leverage and potential for a better top...
Read More >> -
Hematide To Pose Threat to AMGN's Base Business From Late 2011
Friday, November 20, 2009 - 11:15amYaron Werber of Citi maintained his "buy" rating on Amgen Inc (NASDAQ: AMGN). The target price for AMGN is set to $64.00. According to Citi, the market has overlooked competition to Amgen’s Epogen and Aranesp from Hematide. Citi expects this drug to pose threat to AMGN's base business from late...
Read More >>
Yaron Werber
From Benzinga's Newsdesk
- 8:51 AM Liberty Media Corp To Convert Half Its Sirius XM Preferred Stk -WSJ
- 8:50 AM Clorox Sees Bolt-On Deals in Professional Operations, Targets 3-5% Annual Topline Growth
- 08:50 AM UPDATE: Morgan Stanley Initiates Coverage on Intel
- 8:49 AM Merck CEO Says He Isn't Interested in Breaking Up the Company -Bloomberg
- 08:49 AM Stifel Nicolaus Reiterates Hold on Google, Reduces Estimates for Currency Headwinds
- 8:49 AM BioMarin Pharmaceutical Falls 4% Pre-Market on Offering of 6.5M Shares
- 8:48 AM Volcker Proposes Idea for New Global Monetary System, Wants to Defend Equilibrium FX Rates with Wide Trading Bands
- 08:48 AM UPDATE: Morgan Stanley Initiates Coverage on SanDisk
- 08:48 AM Oppenheimer Comments on Google, OpenTable Relationship
- 08:47 AM BioMarin Announces Pricing of Public Offering of Common Stock; 6.5M Shares for $248.885M
- 08:47 AM CPI Aero Announces $3.4 Million in New Orders for Wing Kits
- 8:45 AM UPDATE: Morgan Stanley Says $5.4B in Deposits Held by Citi Will be Transferred
- 08:45 AM Cantor Fitzgerald Comments on CEVA Launches
- 8:43 AM Global Hunter Securities Initiates Coverage on Arch Coal at Neutral
- 08:43 AM UPDATE: Pritchard Capital Markets Initiates Buy, $72 PT on SM Energy
Brain Trust
- UPDATE: Bank of America Raises Protective Life's PO
- UPDATE: Morgan Stanley Initiates Coverage on Intel
- Stifel Nicolaus Reiterates Hold on Google, Reduces Estimates for Currency Headwinds
- Oppenheimer Comments on Google, OpenTable Relationship
- UPDATE: Morgan Stanley Initiates Coverage on SanDisk
- BioMarin Announces Pricing of Public Offering of Common Stock; 6.5M Shares for $248.885M
- CPI Aero Announces $3.4 Million in New Orders for Wing Kits
- Cantor Fitzgerald Comments on CEVA Launches
- UPDATE: Pritchard Capital Markets Initiates Buy, $72 PT on SM Energy
- UPDATE: Maxim Group Upgrades Renren to Hold on Price Depreciation
- Is Facebook Secretly Cloning the iPhone 5?
- David Einhorn's Greenlight Capital Letter to Investors Defends Apple, Doesn't Mention Herbalife
- Was IBM Smart to Ban Siri?
- James Altucher Article Sends Neonode Soaring
- Why Einhorn Is Wrong About Apple
- 5 Small-Cap Short Ideas
- Facebook and Apple Together at Last?
- Stocks to Watch for the All Things Digital Conference: AAPL, ORCL, P, LNKD, ZNGA
- Social Media Chatter on Dell Around Its Earnings Report
- Mako Surgical Recovers After Decline of More Than 40%
